S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
Bank Collapse Causes Gold Prices to Soar (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
Bank Collapse Causes Gold Prices to Soar (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
Bank Collapse Causes Gold Prices to Soar (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
Bank Collapse Causes Gold Prices to Soar (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
NASDAQ:WVE

Wave Life Sciences (WVE) Stock Forecast, Price & News

$3.66
-0.10 (-2.66%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$3.59
$3.81
50-Day Range
$3.56
$4.69
52-Week Range
$1.25
$7.12
Volume
362,200 shs
Average Volume
394,944 shs
Market Capitalization
$360.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Wave Life Sciences MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
91.3% Upside
$7.00 Price Target
Short Interest
Bearish
2.25% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.57
Upright™ Environmental Score
News Sentiment
0.23mentions of Wave Life Sciences in the last 14 days
Based on 20 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.32) to ($1.27) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

297th out of 1,010 stocks

Pharmaceutical Preparations Industry

125th out of 494 stocks


WVE stock logo

About Wave Life Sciences (NASDAQ:WVE) Stock

Wave Life Sciences Ltd. is a clinical-stage genetic medicines company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, optimization, and production of novel stereopure oligonucleotides. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Receive WVE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

WVE Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
The gold catalyst we've waited for
Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
Wave Life Sciences (WVE) Gets a Buy from Mizuho Securities
Wave Life Sciences (NASDAQ:WVE) Upgraded at StockNews.com
See More Headlines
Receive WVE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

WVE Company Calendar

Last Earnings
3/22/2023
Today
5/29/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:WVE
Employees
235
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+91.3%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-161,820,000.00
Net Margins
-1,021.14%
Pretax Margin
-1,016.54%

Debt

Sales & Book Value

Annual Sales
$14.83 million
Book Value
($0.52) per share

Miscellaneous

Free Float
66,696,000
Market Cap
$360.04 million
Optionable
Optionable
Beta
-0.90

Key Executives

  • Paul B. Bolno
    President, Chief Executive Officer & Director
  • Kyle Moran
    Chief Financial Officer
  • Chandra Vargeese
    Chief Technology Officer
  • Christopher Francis
    SVP-Corporate Development & Head-Emerging Areas
  • Anne-Marie Li-Kwai-Cheung
    Chief Development Officer













WVE Stock - Frequently Asked Questions

Should I buy or sell Wave Life Sciences stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" WVE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in WVE, but not buy additional shares or sell existing shares.
View WVE analyst ratings
or view top-rated stocks.

What is Wave Life Sciences' stock price forecast for 2023?

5 equities research analysts have issued 12 month price targets for Wave Life Sciences' stock. Their WVE share price forecasts range from $5.00 to $10.00. On average, they expect the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 91.3% from the stock's current price.
View analysts price targets for WVE
or view top-rated stocks among Wall Street analysts.

How have WVE shares performed in 2023?

Wave Life Sciences' stock was trading at $7.00 at the start of the year. Since then, WVE stock has decreased by 47.7% and is now trading at $3.66.
View the best growth stocks for 2023 here
.

When is Wave Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our WVE earnings forecast
.

How were Wave Life Sciences' earnings last quarter?

Wave Life Sciences Ltd. (NASDAQ:WVE) posted its earnings results on Wednesday, March, 22nd. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.05. The firm had revenue of $1.24 million for the quarter, compared to the consensus estimate of $2.35 million. Wave Life Sciences had a negative net margin of 1,021.14% and a negative trailing twelve-month return on equity of 1,038.84%.

What ETFs hold Wave Life Sciences' stock?

ETFs with the largest weight of Wave Life Sciences (NASDAQ:WVE) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) and Invesco Nasdaq Biotechnology ETF (IBBQ).

What is Paul Bolno, M.D., MBA's approval rating as Wave Life Sciences' CEO?

17 employees have rated Wave Life Sciences Chief Executive Officer Paul Bolno, M.D., MBA on Glassdoor.com. Paul Bolno, M.D., MBA has an approval rating of 92% among the company's employees. This puts Paul Bolno, M.D., MBA in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Wave Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Aduro Biotech (ADRO), Cidara Therapeutics (CDTX), CRISPR Therapeutics (CRSP) and ImmunoGen (IMGN).

What is Wave Life Sciences' stock symbol?

Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

Who are Wave Life Sciences' major shareholders?

Wave Life Sciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Maverick Capital Ltd. (6.71%), BlackRock Inc. (1.43%), FMR LLC (1.05%), Geode Capital Management LLC (0.70%), Bank of America Corp DE (0.58%) and Platinum Investment Management Ltd. (0.46%). Insiders that own company stock include Chandra Vargeese, Chris Francis, Kyle Moran, Paul Bolno and Ra Capital Management, LP.
View institutional ownership trends
.

How do I buy shares of Wave Life Sciences?

Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Wave Life Sciences' stock price today?

One share of WVE stock can currently be purchased for approximately $3.66.

How much money does Wave Life Sciences make?

Wave Life Sciences (NASDAQ:WVE) has a market capitalization of $360.04 million and generates $14.83 million in revenue each year. The company earns $-161,820,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis.

How many employees does Wave Life Sciences have?

The company employs 235 workers across the globe.

How can I contact Wave Life Sciences?

Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The official website for the company is www.wavelifesciences.com. The company can be reached via phone at (656) 236-3388, via email at krausch@wavelifesci.com, or via fax at 617-949-2901.

This page (NASDAQ:WVE) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -